Jubilant Pharmova Limited has announced a major leadership move with the appointment of Daniel J. O’Connor as the new Chief Executive Officer of its proprietary novel drugs business, Jubilant Therapeutics Inc. The company is positioning this transition as a key step in accelerating its innovation-led growth strategy, particularly in the biotech and oncology space.
O’Connor comes with more than three decades of experience in biotechnology, oncology, and executive leadership. His career has been defined by driving value creation around differentiated, IP-rich platforms and steering companies through both scientific and commercial inflection points. Before joining Jubilant Therapeutics, he served as CEO of Ambrx Biopharma, where his leadership contributed to a significant rise in the company’s valuation and ultimately its successful acquisition. His ability to guide organizations through strategic transitions has become one of his defining strengths.
Earlier in his career, O’Connor played a crucial role at ImClone Systems, where he was involved in the clinical development, launch and commercialization of a major oncology therapy. His work required navigating highly complex intellectual property and inventorship matters, giving him deep expertise in handling scientific assets with global commercial potential. He also led Advaxis, a NASDAQ-listed immuno-oncology company, transforming it into a late-stage clinical organization while securing vital growth capital and establishing strategic partnerships with leading pharmaceutical players.
With his appointment, Jubilant Pharmova signals a renewed focus on strengthening its proprietary drug development pipeline and scaling Jubilant Therapeutics’ presence in the global biotech arena. The company expects O’Connor’s experience across clinical development, commercialization, and corporate strategy to bring sharper momentum to its innovation roadmap.
